CP
MIRM icon

CenterBook Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

CenterBook Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
19,702
-25,665
-57% -$2.41M 0.1% 252
2025
Q4 		$3.58M Buy
45,367
+37,010
+443% +$2.66M 0.18% 165
2025
Q3 		$613K Buy
+8,357
New +$531K 0.03% 442
2024
Q4 		– Sell
-11,530
Closed -$450K – 548
2024
Q3 		$450K Sell
11,530
-23,355
-67% -$932K 0.03% 399
2024
Q2 		$1.19M Sell
34,885
-87,572
-72% -$2.3M 0.07% 319
2024
Q1 		$3.08M Buy
122,457
+70,620
+136% +$1.94M 0.21% 179
2023
Q4 		$1.53M Buy
51,837
+36,699
+242% +$1.11M 0.19% 183
2023
Q3 		$478K Sell
15,138
-12,984
-46% -$356K 0.06% 338
2023
Q2 		$728K Sell
28,122
-26,231
-48% -$698K 0.09% 284
2023
Q1 		$1.31M Sell
54,353
-111
-0.2% -$2.53K 0.18% 179
2022
Q4 		$1.06M Buy
+54,464
New +$1.08M 0.17% 189
2022
Q3 		– Sell
-14,659
Closed -$285K – 424
2022
Q2 		$285K Sell
14,659
-3,737
-20% -$88.1K 0.06% 332
2022
Q1 		$405K Buy
18,396
+1,651
+10% +$33.7K 0.14% 237
2021
Q4 		$267K Buy
+16,745
New +$260K 0.16% 218

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CenterBook Partners's MIRM Position: Q1 2026 in Review

CenterBook Partners reduced its Mirum Pharmaceuticals (MIRM) stake by 57% in Q1 2026, selling an estimated $2.41M and leaving 19,702 shares worth $1.82M. The position accounts for 0.1% of the portfolio, ranked #252.

CenterBook Partners first reported a position in MIRM in Q4 2021 and has held it in 14 quarters since. The position peaked at $3.58M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • CenterBook Partners held 19,702 shares of Mirum Pharmaceuticals worth $1.82M as of Q1 2026.
  • CenterBook Partners sold 25,665 Mirum Pharmaceuticals shares in Q1 2026, an estimated $2.41M.
  • Mirum Pharmaceuticals made up 0.1% of CenterBook Partners's portfolio in Q1 2026, its #252 holding.
  • CenterBook Partners first reported a position in Mirum Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • CenterBook Partners's Mirum Pharmaceuticals position peaked at $3.58M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.